Scholar Rock (NASDAQ: SRRK) Stock Rises As Company Removes Novo Nordisk Facility From FDA Drug Application

Shares of Scholar Rock (NASDAQ: SRRK) closed 2% higher on Friday after the Cambridge, Massachusetts-based biotech removed a controversial Novo Nordisk-owned facility from its FDA filing for apitegromab. The company confirmed it has, in accordance with FDA guidance, removed Catalent Indiana, a fill-finish plant now owned by Novo Nordisk, from its U.S. biologics license application […] The post…